Preventing Thrombotic Complications in ACS: State of the Art

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

Jacob A. Udell, MD, MPH, Marc P. Bonaca, MD, MPH, Jean-Philippe Collet, MD, PhD, A. Michael Lincoff, MD, Dean J. Kereiakes, MD, Francesco Costa, MD, Cheol.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

NSTE Acute Coronary Syndromes

Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

_________________ Caitlin M. Gibson, PharmD, BCPS

Figure 1 Ischaemic endpoints

Antiplatelet Therapy For STEMI: The Case for Cangrelor

Ischaemic Heart Disease Acute Coronary Syndrome

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

European and US Guidelines

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Oral Anticoagulation and Preventing Stent Thrombosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Achieving Long-Term Protection Post-MI

PAD Patients vs Post-ACS Patients:

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Glenn N. Levine et al. JACC 2016;68:

Unmet Needs in the Secondary Prevention in ACS

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

What Has Been Tried and What Is True?

Tailoring Antiplatelet Therapy in PCI

Recurrent Angina: New Tools for an Old Problem

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Heart Failure Prevention: Mission Impossible?

T2DM and CV Outcomes Trials: A Deep Dive!

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Treatment Options to Consider

European Heart Association Journal 2007 April

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Would you recommend extending DAPT >1 year post-MI?

Five Things You Need to Know About Secondary Prevention Post-ACS

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

CV Risk Doesn't End in the Cath Lab

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

What oral antiplatelet therapy would you choose?

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Improving Adherence to Antiplatelet Therapy After an ACS Event

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

ESC Guideline on the Management of STEMI Recommendation for DAPT

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Section C: Clinical trial update: Oral antiplatelet therapy

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Preventing Thrombotic Complications in ACS: State of the Art

79-Year-Old Woman: Presentation

79-Year-Old Woman (cont)

GRACE ACS Risk Model: Score in-hospital to 6 Months

GRACE ACS Risk Model: Risk in-hospital to 6 Months

79-Year-Old Woman: CCU

79-Year-Old Woman (cont)

79-Year-Old Woman: Catheterization

79-Year-Old Woman: CABG

79-Year-Old Woman: Discharge

79-Year-Old Woman: Stable Angina

Prasugrel in the Elderly

PLATO: All-cause Mortality in the Overall and CABG Subpopulation

PLATO: All-cause Death and Major Bleeding in the CKD Subgroup

PLATO CABG Substudy: Bleeding-related Deaths at 12 Months

2015 ESC Guidance on Use of Antiplatelet Therapy in NSTE-ACS

2015 ESC Guidance on Interrupting Antiplatelet Therapy in NSTE-ACS

39-Year-Old Man: Presentation

39-Year-Old Man: Medical History

39-Year-Old Man: Vital Signs and Physical Exam

39-Year-Old Man: ECG

39-Year-Old Man: Transferred for Cath

39-Year-Old Man: Coronary Angiogram, 3:19 PM

39-Year-Old Man: 3:19 PM

39-Year-Old Man: 3:24 PM

39-Year-Old Man: 3:27 PM

39-Year-Old Man: 3:34 PM

39-Year-Old Man: Final Result

39-Year-Old Man: Antiplatelet Therapy

39-Year-Old Man: 2 Days Post-STEMI

39-Year-Old Man: 1 Year Post-STEMI

DAPT: Long-term DAPT in DES Patients, Months 12-30

DAPT: GUSTO Bleeding, Severe or Moderate, Months 12-30

DAPT: Major Adverse CV and Cerebrovascular Events by Subgroup

DAPT: Mortality Outcomes

DAPT: Outcomes at 12 to 30 Months Post-Stent, MI/No MI

PEGASUS-TIMI 54: Trial Design

PEGASUS-TIMI 54: Primary Endpoint

PEGASUS-TIMI 54: Subgroup Analysis of the Primary Endpoint

PEGASUS-TIMI 54: Bleeding Outcomes

Extended Dual Antiplatelet Therapy vs Aspirin Alone: Meta-analysis

DAPT Risk Score

Abbreviations

Abbreviations (cont)

Abbreviations (cont)